49 / 74 · 0:59 · Original AXON film
VK2735
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
GIP and GLP-1 research
VK2735 activates GIP and GLP-1 receptors. Its research includes different formulations, making the route of administration an important part of every evidence claim. [1] [2]
VENTURE | injectable formulation
The phase two VENTURE study tested the injectable formulation against placebo in adults with obesity or overweight and a related condition, excluding diabetes. [1] [2]
13-week results
Over 13 weeks, the study reported greater body-weight reduction with VK2735. The most common adverse events were gastrointestinal. These are short-term trial findings. [1] [2]
Oral evidence is separate
An oral formulation needs its own evidence on absorption, tolerability, and outcomes. Results from an injectable study cannot establish equivalent performance for a tablet or an unrelated research product. [1] [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- VENTURE investigators (2026): Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management →Injectable trial design, population, 13-week weight findings, and gastrointestinal adverse events.
- Viking Therapeutics (2026): Initiation of VK2735 oral phase 3 clinical program →Separate oral development program and route distinction.
